In analogy to the successful targeting of the IL-17 axis in psoriasis, the anti-IL-17A antibody secukinumab and the IL-17R targeting antibody brodalumab were evaluated in clinical trials with IBD patients, but these trials unexpectedly had to be terminated. The gene discussed is IL17A; the disease is inflammatory bowel disease.